Shionogi & Co., Ltd. (4507) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shionogi & Co., Ltd. (4507:JPX), powered by AI.

Current Price
¥2,841
P/E Ratio
14.2
Market Cap
2.4T
Sector
Healthcare
What is the Shionogi & Co., Ltd. stock price forecast?

Shionogi & Co., Ltd. is currently trading at ¥2,841. View real-time AI analysis on Alpha Lenz.

What is Shionogi & Co., Ltd. insider trading activity?

View the latest insider trading data for Shionogi & Co., Ltd. on Alpha Lenz.

What is Shionogi & Co., Ltd.'s P/E ratio?

Shionogi & Co., Ltd.'s P/E ratio is 14.2.

Shionogi & Co., Ltd.

¥2.84K
JPX4507
Ask about Shionogi & Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Shionogi & Co., Ltd. trades at a P/E of 14.2 (undervalued) with solid ROE of 13.1%. Operating margin of 35.7% indicates strong profitability.

Ask for details

Company Overview

Shionogi & Co., Ltd. is a leading pharmaceutical company specializing in the research, development, and distribution of pharmaceutical products. Established in Japan in 1878, Shionogi focuses primarily on three therapeutic areas: infectious diseases, pain/CNS, and oncology. The company is known for its commitment to innovation in drug discovery, aiming to address unmet medical needs through advanced healthcare solutions. Notably, Shionogi has made significant contributions to the development of anti-infective medications, including antibiotics and antiviral treatments, positioning itself as a key player in the fight against global health challenges. In addition to pharmaceuticals, Shionogi expands its reach through ventures in healthcare services and bioinformatics. As a prominent entity in the pharmaceutical industry, Shionogi holds strategic partnerships with various global companies and research institutions, enhancing its impact on the international market. With a dedication to enhancing the quality of life, Shionogi & Co., Ltd. continues to play a crucial role in addressing critical health issues through its innovative solutions and robust product pipeline.

CEODr. Isao Teshirogi Ph.D.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees4,955

Company Statistics

(FY 2025)

Profile

Market Cap¥2,416.66B
Revenue¥438.27B
Shares Out0.00
Employees4,955

Margins

Gross85.44%
EBITDA52.64%
Operating35.73%
Pre-Tax45.81%
Net38.68%

Valuation

P/E14.18
P/B1.77
EV/Sales5.51
EV/EBITDA8.95
P/FCF16.86

Growth (CAGR)

Rev 3Yr9.36%
Rev 5Yr5.62%
Op Inc 3Yr12.39%
Op Inc 5Yr3.69%
Net Inc 3Yr14.33%
Net Inc 5Yr6.77%

Returns

ROA11.48%
ROE13.12%
ROIC14.21%

Financial Health

Cash & Cash Equivalents¥374.80B
Net Debt¥-201.94B
Debt/Equity12.69%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Shionogi & Co., Ltd. (Healthcare) Stock Forecast & Analysis ¥2,841 | Alpha Lenz